Market Cap
$331.9M
LRMR
Larimar Therapeutics, Inc.
$2.95 ▼ -3.43%
Prev close $3.06Market cap$331.9M
ConsensusStrong Buy
12-mo target$14.40 (+387.3%)
▲ Bullish
Analyst conviction 9/10
Insider Buying Cluster (4 insiders)High Impact Filing (7/10)38 New Institutional Positions12 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on LRMR right now — valuation, ownership and activity at a glance.
Cap Size
Small Cap
Analyst Consensus
Strong Buy (94%)
Inst. Holders
50 funds
Inst. Value
$124.4M
Inst. Activity
38 buys / 12 sells
Insider Activity
$25.7M buy / $0.00 sell
Insider Net $
$25.7M
Social Sentiment
69° Warm
SEC Reports
5
Press Releases
1
Price chart 30d -23.6%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 29, 2026 leadership
Larimar Therapeutics Strengthens Executive Leadership with Appointment of John Harlow as President and Chief Operating Officer
BALA CYNWYD, Pa., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: L
Sep 29, 2026 Insider
Harlow John B. Jr. was granted 50,000 shares
President and COO
Sep 29, 2026 Insider
Harlow John B. Jr. was granted 800,000 shares
President and COO
Jul 6, 2026 Insider
Hamilton Thomas Edward bought 50,000 shares
Director @ $3.34 ($166.9K)
Jun 30, 2026 Inst.
BlackRock, Inc. — ADD
5,678,035 shares ($17.3M)
Jun 30, 2026 Inst.
May 14, 2026 SEC RTW INVESTMENTS, LP — ADD
2,565,999 shares ($7.8M)
Larimar Therapeutics reported Q1 2026 net loss of $29.6M ($0.31/share), roughly in line with the $29.3M loss in Q1 2025,
8-K — Impact 7/10
Larimar Therapeutics reported Q1 2026 EPS of -$0.31, beating consensus of -$0.57 by 45.6%, with no revenue. The company
PRESS-RELEASE — Impact 7/10
Analyst ratings buy % +0.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
94% rate it Buy or better · 17 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Aug 5, 2026 | Wedbush | MAINTAIN | Outperform | 57% |
| Jun 30, 2026 | Baird | MAINTAIN | Outperform | 54% |
| May 27, 2026 | JP Morgan | INITIATE | Overweight | 55% |
| May 18, 2026 | Wedbush | MAINTAIN | Outperform | 57% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 8 | 8 | 1 | 0 | 0 | 94% | |
| Aug 1, 2026 | 8 | 8 | 1 | 0 | 0 | 94% | |
| Jul 1, 2026 | 8 | 7 | 1 | 0 | 0 | 94% | |
| Jun 1, 2026 | 8 | 7 | 1 | 0 | 0 | 94% | |
| May 1, 2026 | 9 | 7 | 1 | 0 | 0 | 94% | |
| Apr 1, 2026 | 9 | 7 | 1 | 0 | 0 | 94% | |
| Mar 1, 2026 | 9 | 7 | 1 | 0 | 0 | 94% | |
| Feb 1, 2026 | 9 | 7 | 1 | 0 | 0 | 94% |
Price targets
Where 10 covering analysts think LRMR trades over the next 12 months.
$14.40 +387.3% upside Strong Buy
Current$2.96 Low$5.00 Median$13.00 High$26.00 10 analysts
$5.00$26.00
Analyst rating Strong Buy· 1.2/5 as of Oct 2, 2026
Social media sentiment mood +0.0%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
69°
Warm
BearishNeutralBullish
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
5 SEC filing reports analyzed · 4 bullish, 0 bearish, 0 mixed, 1 neutral · avg impact 6.6/10.Plus 1 press releases.
BULLISH8-K7/10
Larimar Therapeutics reported Q1 2026 net loss of $29.6M ($0.31/share), roughly in line with the $29
May 14, 2026
BULLISHPRESS-RELEASE7/10
Larimar Therapeutics reported Q1 2026 EPS of -$0.31, beating consensus of -$0.57 by 45.6%, with no r
May 14, 2026
BULLISHCLUSTER8/10
Four insiders at Larimar Therapeutics collectively purchased $6.07 million in shares over a single d
Mar 3, 2026
BULLISHCLUSTER6/10
Three insiders at Larimar Therapeutics collectively purchased $550,000 worth of shares in open-marke
Mar 2, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 29, 2026
leadership
Larimar Therapeutics Strengthens Executive Leadership with Appointment of John Harlow as President and Chief Operating Officer
BALA CYNWYD, Pa., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focus
Sep 25, 2026
short_volume
Short Volume: LRMR — 83.4% short (1.1M / 1.4M)
Short: 1,146,150 | Exempt: 37,319 | TRF Vol: 1,373,472 | Short Ratio: 83.4% | Off-exchange volume (dark pool + OTC)
Sep 24, 2026
short_volume
Short Volume: LRMR — 83.5% short (1.5M / 1.7M)
Short: 1,455,755 | Exempt: 38,036 | TRF Vol: 1,743,472 | Short Ratio: 83.5% | Off-exchange volume (dark pool + OTC)
Sep 23, 2026
short_volume
Short Volume: LRMR — 75.1% short (0.8M / 1.1M)
Short: 796,046 | Exempt: 2 | TRF Vol: 1,059,390 | Short Ratio: 75.1% | Off-exchange volume (dark pool + OTC)
Sep 18, 2026
short_volume
Short Volume: LRMR — 73.8% short (0.4M / 0.5M)
Short: 378,093 | Exempt: 0 | TRF Vol: 512,022 | Short Ratio: 73.8% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.35 | $-0.37–$-0.31 | 42.8% | +0.0% | 6↑ 0↓ | $0.0B | 7 |
| Next Q | $-0.38 | $-0.45–$-0.34 | 47.3% | +0.0% | 6↑ 0↓ | $0.0B | 7 |
| Current FY | $-1.35 | $-1.49–$-1.14 | 40.5% | +0.0% | 6↑ 0↓ | $0.0B | 7 |
| Next FY | $-1.06 | $-1.49–$-0.29 | 21.5% | +0.0% | 5↑ 0↓ | $0.0B | 8 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.349 | — |
| 7d ago | $-0.349 | — |
| 30d ago | $-0.349 | — |
| 60d ago | $-0.421 | +0.072 |
| 90d ago | $-0.421 | +0.073 |
Institutional ownership
Which big funds own LRMR (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $124.4M total value (40,685,362 shares) as of 2026-Q2. Top holders: BlackRock,, DRIEHAUS, VANGUARD. Net buying activity: 38 institutions added/increased vs 12 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BlackRock, Inc. | 5,678,035 | $17.3M | 13.9% | ADD +51.3% |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 3,163,423 | $9.6M | 7.8% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 2,974,901 | $9.1M | 7.3% | — |
| RTW INVESTMENTS, LP | 2,565,999 | $7.8M | 6.3% | ADD +71.1% |
| AQR CAPITAL MANAGEMENT LLC | 2,371,414 | $7.2M | 5.8% | — |
| MARSHALL WACE, LLP | 2,012,458 | $6.1M | 4.9% | DOUBLED +115.6% |
| GOLDMAN SACHS GROUP INC | 1,752,910 | $5.3M | 4.3% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 1,679,003 | $5.1M | 4.1% | ADD +51.4% |
| Qube Research & Technologies Ltd | 1,641,042 | $5.0M | 4.0% | ADD +93.6% |
| CITADEL ADVISORS LLC | 1,456,825 | $4.4M | 3.6% | DOUBLED +180.6% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | ADD | 3,752,200 | 5,678,035 | +51.3% | $17.3M |
| RTW INVESTMENTS, LP | ADD | 1,500,000 | 2,565,999 | +71.1% | $7.8M |
| MARSHALL WACE, LLP | DOUBLED | 933,464 | 2,012,458 | +115.6% | $6.1M |
| GEODE CAPITAL MANAGEMENT, LLC | ADD | 1,108,761 | 1,679,003 | +51.4% | $5.1M |
| Qube Research & Technologies Ltd | ADD | 847,644 | 1,641,042 | +93.6% | $5.0M |
| CITADEL ADVISORS LLC | DOUBLED | 519,132 | 1,456,825 | +180.6% | $4.4M |
| STATE STREET CORP | ADD | 911,326 | 1,411,804 | +54.9% | $4.3M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | DOUBLED | 406,558 | 1,403,172 | +245.1% | $4.3M |
| MILLENNIUM MANAGEMENT LLC | TRIM | 3,625,278 | 1,333,037 | -63.2% | $4.1M |
| FMR LLC | DOUBLED | 63,570 | 937,368 | +1374.5% | $2.9M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
7 insiders, 16 transactions. Net $25.7M — $25.7M bought, $0.00 sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 29, 2026 | Harlow John B. Jr. | President and COO | AWARD | 50,000 | — | — |
| Sep 29, 2026 | Harlow John B. Jr. | President and COO | AWARD | 800,000 | — | — |
| Jul 6, 2026 | Hamilton Thomas Edward | Director | BUY | 50,000 | $3.34 | $166.9K |
| May 19, 2026 | THOMAS FRANK E | Director | AWARD | 55,150 | — | — |
| May 19, 2026 | Hamilton Thomas Edward | Director | AWARD | 55,150 | — | — |
| May 19, 2026 | Truitt Joseph | Director | AWARD | 55,150 | — | — |
| May 19, 2026 | SHERMAN JEFFREY W | Director | AWARD | 55,150 | — | — |
| May 19, 2026 | LEFF JONATHAN S | Director | AWARD | 55,150 | — | — |
| May 19, 2026 | Flynn James E | Director | AWARD | 55,150 | — | — |
| Feb 27, 2026 | Flynn James E | Director | BUY | 2,000,000 | $5.00 | $10.0M |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for LRMR.
Shares short
13,894,306
Settlement Sep 15, 2026
Change vs prior
+1.3%
Semi-monthly cycle
Days to cover
14.9
At avg daily volume
Of shares outstanding
≈13.4%
Estimate — not % of float
All LRMR filing & press-release reports (6)
- 8-K reportMay 14, 2026
- PRESS-RELEASE reportMay 14, 2026
- PRESS-RELEASE reportMar 19, 2026
- CLUSTER reportMar 3, 2026
- CLUSTER reportMar 2, 2026
- 8-K reportFeb 27, 2026